Prenetics Global (NASDAQ:PRE) Cut to “Hold” at Wall Street Zen

Wall Street Zen cut shares of Prenetics Global (NASDAQ:PRE) from a buy rating to a hold rating in a research note published on Monday.

PRE has been the topic of several other reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Prenetics Global in a research note on Thursday, January 22nd. Cantor Fitzgerald boosted their target price on Prenetics Global from $26.00 to $32.00 and gave the stock an “overweight” rating in a report on Wednesday, October 29th. Finally, Roth Mkm assumed coverage on Prenetics Global in a report on Wednesday, February 11th. They set a “buy” rating and a $36.00 price target for the company. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $34.00.

Prenetics Global Stock Down 7.7%

Shares of PRE opened at $20.06 on Monday. The stock’s 50-day moving average price is $17.68 and its 200 day moving average price is $13.88. The firm has a market capitalization of $337.61 million, a price-to-earnings ratio of -9.88 and a beta of 0.35. Prenetics Global has a 12-month low of $3.09 and a 12-month high of $22.86.

Institutional Trading of Prenetics Global

Several hedge funds have recently added to or reduced their stakes in PRE. Quadrature Capital Ltd acquired a new position in shares of Prenetics Global in the fourth quarter valued at approximately $468,000. Millennium Management LLC bought a new stake in Prenetics Global in the 4th quarter valued at $810,000. Manatuck Hill Partners LLC acquired a new position in Prenetics Global in the 4th quarter worth $170,000. Boothbay Fund Management LLC bought a new position in Prenetics Global during the 4th quarter worth about $241,000. Finally, 683 Capital Management LLC acquired a new stake in shares of Prenetics Global in the 4th quarter valued at about $1,181,000. Institutional investors and hedge funds own 25.01% of the company’s stock.

Key Prenetics Global News

Here are the key news stories impacting Prenetics Global this week:

• Positive Sentiment: Completed sale of Insighta stake to Tencent for $70M, boosting cash and liquidity to $171.1M and leaving Prenetics with zero debt — strengthens the balance sheet and provides non‑dilutive capital to accelerate IM8’s global expansion. Prenetics Completes $70 Million Insighta Sale to Tencent
• Positive Sentiment: Record Q4 and full‑year 2025 results driven by IM8: management reports IM8 hit $120M ARR in 12 months and consolidated revenue surged ~480% YoY — supports a growth narrative around the consumer health brand (key driver of future value). Prenetics Reports Record Q4 and FY 2025 Results
• Positive Sentiment: Quarterly EPS beat: reported EPS of ($0.27) vs. consensus ($0.49) — a modest beat that may reassure investors on near‑term operational execution. Slide deck and call available for details. Prenetics Earnings and Conference Call
• Positive Sentiment: Board strengthening: appointment of Dr. Darshan Shah adds longevity and health‑tech expertise that aligns with IM8’s strategic focus. Prenetics Appoints Dr. Darshan Shah to Board
• Neutral Sentiment: Market commentary is noting the stock’s strong headline growth and recent catalysts; some intraday moves reflect momentum trading around the news rather than changes to fundamentals. Is Prenetics Surprising Markets?
• Negative Sentiment: Profitability and longer‑term guidance remain concerns: the company still shows a negative net margin (~60.7%) and negative return on equity (~‑30.1%); analysts expect a materially negative FY EPS (consensus ~‑3.3), and management discloses risks (including exposure to Bitcoin holdings). These raise execution and path‑to‑profitability questions despite top‑line momentum. Prenetics Q4 Press Release / Slides

About Prenetics Global

Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.

Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.